SCHEMBL4803000

SCHEMBL4803000

Cn1cnc(-c2ccc(O)cc2)c1-c1cc2c(N)ncnc2s1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 8/20 0.79
KDR P35968 3/20 0.79
FLT1 P17948 2/20 0.79
LIMK1 P53667 2/20 0.39
FGFR1 P11362 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
MCL1 Q07820 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PIK3CG P48736 2/20 0.37
PIK3CA P42336 2/20 0.37
PIK3CD O00329 1/20 0.37
ABL1 P00519 1/20 0.37
EGFR P00533 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4802343 0.91 TEK (0.83) TEKKDRFLT1LIMK1ALDH1A1
SCHEMBL4806052 0.89 TEK (0.79) TEKKDRFLT1FGFR1ALDH1A1
SCHEMBL4797768 0.89 TEK (0.79) TEKKDRFLT1MEN1KMT2A
SCHEMBL4796404 0.89 TEK (0.79) TEKKDRFLT1ALDH1A1SMN1; SMN2
SCHEMBL4800818 0.89 TEK (0.79) TEKKDRFLT1ALDH1A1KDM4E
SCHEMBL4802939 0.88 TEK (1.00) TEKKDRFLT1ALDH1A1KDM4E
SCHEMBL4802728 0.87 TEK (0.76) TEKKDRFLT1LIMK1ALDH1A1
SCHEMBL4802652 0.84 TEK (0.80) TEKKDRFLT1PIK3CGPIK3CA
SCHEMBL4466113 0.83 TEK (0.81) TEKKDRFLT1LIMK1ALDH1A1
SCHEMBL4797251 0.83 TEK (0.76) TEKKDRFLT1GAAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7427616-B2 Condensed pyridines and pyrimidines with tie2 (TEK) activity ASTRAZENECA AB (SE) 2008-09-23 US claimed
EP-1537112-B1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2006-04-19 EP claimed
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity ASTRAZENECA AB (SE) 2005-11-17 US claimed
US-7427616-B2 Condensed pyridines and pyrimidines with tie2 (TEK) activity ASTRAZENECA AB (SE) 2008-09-23 US disclosed
EP-1537112-B1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2006-04-19 EP disclosed
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity ASTRAZENECA AB (SE) 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity TIE1, TEK, KDR TEK 2/4885KDR 3/4885FLT1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.